Medical Xpress - Cardiology

FEBRUARY 14, 2025

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.

Heart Attack 139

Heart Attack Heart attacks Research Kidney Disease 139

Med Page Today

FEBRUARY 14, 2025

(MedPage Today) -- The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular risk factors, a prespecified.

Kidney Disease 88

Kidney Disease Heart Attack Heart attacks Diabetes 88

DAIC

APRIL 6, 2024

However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes.

Heart Attack 98

Heart Attack Heart attacks Heart Failure Outpatient 98

Science Daily - Heart Disease

FEBRUARY 14, 2025

New research shows sotagliflozin is the only drug in its class to demonstrate these results.

Heart Attack 112

Heart Attack Heart attacks Kidney Disease Heart Failure 112

DAIC

APRIL 6, 2024

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24,

Heart Attack 81

Heart Attack Heart attacks Heart Failure Outcomes 81

DAIC

APRIL 7, 2024

High blood pressure, or hypertension , is a leading cause of heart attacks, strokes and death. It occurs when the heart has to work harder to push blood through the blood vessels, increasing pressure inside the vessels. Centers for Disease Control and Prevention (CDC) estimates that nearly half of U.S.

Blood Pressure 111

Blood Pressure Heart Attack Heart attacks Hypertension 111

DAIC

JANUARY 23, 2024

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111